News & Updates

Use of oral semaglutide results in substantial decreases in alcohol consumption, alcohol craving, alcohol-related problems, and cannabis use among individuals seeking treatment from alcohol use disorder (AUD), a study has shown.

Exposure to immune checkpoint inhibitors (ICIs) among cancer patients may predispose them to coeliac disease, according to a large real-world study.

Adjunctive azithromycin use during unscheduled cesarean deliveries has increased following the landmark C/SOAP trial in 2016, resulting in a decrease in postpartum infection rates in a real-world US cohort.

Atypical otopathogens of otitis media (OM) are more commonly detected in older children and correlate with distinct disease phenotypes but similar outcomes to typical pathogens, according to a study.

Higher prepubertal urinary metabolites of glucocorticoids, androgens, and progesterone tend to speed up pubertal onset in girls, especially in those with high BMI and stress, a study has found.

In the phase III PROPEL 3 trial, once-daily treatment with infigratinib results in a significantly greater increase in annualized height velocity (AHV) in children with achondroplasia.

The selective, oral, central nervous system-penetrant reversible RIPK1 inhibitor SAR443820 appears to have limited clinical benefit in amyotrophic lateral sclerosis (ALS) and is even associated with greater hepatic enzyme increase, according to the phase II HIMALAYA trial.

Treatment with aficamten significantly improves patient-reported health status and exercise capacity in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM), according to the ACACIA-HCM trial presented at ESC 2026.